Crowdonomics
All companies

Emerald Health Bioceuticals Inc.

Operating

Biotech · San Diego, CA

Estimated pre-money ⓘ
$31.3M
As of Feb 2020 · from Reg A Offering (2020) · our estimate: offering price × shares outstanding, not a stated valuation
Total raised
$179,006
Crowd $0 · Private $179K · 3 rounds since 2017
Latest share price
$5.00
Reg A Offering (2020) offering price

Financials

FY2018 · from SEC filings · hover any figure for its source
$654K
−$2.3M
2018
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2018 audited
Income statement
Revenue
$654,493
Cost of goods sold
$486,379
Gross margin
26%
Net income
-$2,330,694
Balance sheet
Cash
$425,698
Accounts receivable
$294,704
Total assets
$2,715,344
Long-term debt
$0
Total liabilities
$7,452,575
Other
Headcount
6

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$31.3M
est. pre-money
Reg A+ · Equity · Feb 2020

Dotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.

Cap table

Share counts as of Mar 23, 2020
ClassOutstandingVotes / shareShare of totalLast price
Common Stock6,263,000—100.0%—

Shares outstanding over timein today's share terms

6.3M3.1M0
Dec 2018Mar 2020
Common StockRound openedSplit / conversion

Changes in named holdersshares in today's terms · % of all shares at the time

Principal holders% as the filing states it, Mar 23, 2020

  • Emerald Health Sciences Inc.8,662,076 shares82.0%of company
  • Greater than10.0%of company
  • Everyone else (not named in filings)8%

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Raised $52KInvestors 5
Raised $0 / $50MEst. pre-money $31.3M
Raised $127KInvestors 8

Team

7 people
Gaetano Morello
Chief Executive Officer
Elena Traistaru
Chief Financial Officer
Stuart Hutchinson
Vice President of Sales
Tu Diep
President
Punit Dhillon
Chairman of the Board, Director
Jim Heppell
Director
Margaret Dalesandro
Director

Names and titles as disclosed on SEC Form 1-A. Bios and photos come from the platform campaign page and may be out of date.

SEC filings

  • Form 1-A/AMar 23, 20200001594062-20-000021
    EDGAR
  • Form DMar 19, 20200001567619-20-006776
    EDGAR
  • Form 1-AFeb 18, 20200001594062-20-000010
    EDGAR
  • Form D/AAug 17, 20170001713164-17-000002
    EDGAR
  • Form DJul 27, 20170001713164-17-000001
    EDGAR
Source: SEC EDGARCIK 0001713164DEShare price $5.00Last synced Aug 16, 2026

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.